The Latin America, Middle East and Africa Dry Eye Syndrome Treatment Market would witness market growth of 9.8% CAGR during the forecast period (2022-2028).
A number of medical issues, or a side effect from some medications can all cause a decrease in tear production. Due to higher tear evaporation, environmental factors including wind and dry weather can also cause a decrease in tear volume. Dry eye signs can arise if the tears dissipate too rapidly or do not cover the cornea evenly owing to faults within any of the tear layers. As people age naturally, they can have dry eyes. The majority of adults over 65 have some dry eye problems. Because of hormonal changes brought on by menopause, oral contraceptive use, and pregnancy, women are far more likely to have dry eyes.
Also, tear production may be decreased by some drugs, including blood pressure medications, antihistamines, decongestants, and antidepressants. Dry eye symptoms are more prevalent in people with thyroid issues, diabetes, and rheumatoid arthritis. Dry eyes can also be brought on by issues with eyelid inflammation (blepharitis), infection of the eye's surface, or the outward or inward turning of the eyelids. In addition, dry eye symptoms can be exacerbated by exposure to smoke, wind, and dry environments. The eyes can dry up as a result of irregular blinking, which can happen when staring at a screen for extended periods of time, for example. DED might occur as a result of prolonged contact lens wear. It can be exacerbated by refractive eye surgery, such as LASIK, which can reduce tear production.
In a population over 40 years old in Brazil, a prior study employing the Women's Health Study (WHS) Dry Eye Symptom Survey revealed an overall prevalence of DED of 12.8%. In terms of socioeconomics and climate, the nation is diverse. The results of a previous study's sample involving thousands of participants from the five geographical areas of the country suggest that about 27 million people in Brazil as a whole are expected to have DED symptoms.
The predominance of dry eye syndrome has increased as a result of people's changing lifestyles, particularly their greater use of electronic devices like computers and TVs. Additionally, the growing elderly population is more susceptible to diseases like benign prostatic hyperplasia and high blood pressure, which increases the likelihood of getting dry eye syndrome. These factors have boosted the stronghold of the dry eye syndrome treatment market in this region.
The Brazil market dominated the LAMEA Dry Eye Syndrome Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $159.5 million by 2028. The Argentina market is registering a CAGR of 10.4% during (2022-2028). Additionally, The UAE market would showcase a CAGR of 9.5% during (2022-2028).
Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drug, the market is segmented into Restasis, Xiidra, Cequa, Eysuvis and Tyrvaya & Others. Based on Dosage, the market is segmented into Eye drops, Gels, Capsules & Tablets, Eye Solutions and Ointments. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Sales Channel, the market is segmented into OTC and Prescription. Based on Product, the market is segmented into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Services, Inc.), AbbVie, Inc., Bausch + Lomb Corporation (Bausch Health Companies, Inc.), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Inc., and Otsuka Pharmaceutical Co., Ltd.
A number of medical issues, or a side effect from some medications can all cause a decrease in tear production. Due to higher tear evaporation, environmental factors including wind and dry weather can also cause a decrease in tear volume. Dry eye signs can arise if the tears dissipate too rapidly or do not cover the cornea evenly owing to faults within any of the tear layers. As people age naturally, they can have dry eyes. The majority of adults over 65 have some dry eye problems. Because of hormonal changes brought on by menopause, oral contraceptive use, and pregnancy, women are far more likely to have dry eyes.
Also, tear production may be decreased by some drugs, including blood pressure medications, antihistamines, decongestants, and antidepressants. Dry eye symptoms are more prevalent in people with thyroid issues, diabetes, and rheumatoid arthritis. Dry eyes can also be brought on by issues with eyelid inflammation (blepharitis), infection of the eye's surface, or the outward or inward turning of the eyelids. In addition, dry eye symptoms can be exacerbated by exposure to smoke, wind, and dry environments. The eyes can dry up as a result of irregular blinking, which can happen when staring at a screen for extended periods of time, for example. DED might occur as a result of prolonged contact lens wear. It can be exacerbated by refractive eye surgery, such as LASIK, which can reduce tear production.
In a population over 40 years old in Brazil, a prior study employing the Women's Health Study (WHS) Dry Eye Symptom Survey revealed an overall prevalence of DED of 12.8%. In terms of socioeconomics and climate, the nation is diverse. The results of a previous study's sample involving thousands of participants from the five geographical areas of the country suggest that about 27 million people in Brazil as a whole are expected to have DED symptoms.
The predominance of dry eye syndrome has increased as a result of people's changing lifestyles, particularly their greater use of electronic devices like computers and TVs. Additionally, the growing elderly population is more susceptible to diseases like benign prostatic hyperplasia and high blood pressure, which increases the likelihood of getting dry eye syndrome. These factors have boosted the stronghold of the dry eye syndrome treatment market in this region.
The Brazil market dominated the LAMEA Dry Eye Syndrome Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $159.5 million by 2028. The Argentina market is registering a CAGR of 10.4% during (2022-2028). Additionally, The UAE market would showcase a CAGR of 9.5% during (2022-2028).
Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drug, the market is segmented into Restasis, Xiidra, Cequa, Eysuvis and Tyrvaya & Others. Based on Dosage, the market is segmented into Eye drops, Gels, Capsules & Tablets, Eye Solutions and Ointments. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Sales Channel, the market is segmented into OTC and Prescription. Based on Product, the market is segmented into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Services, Inc.), AbbVie, Inc., Bausch + Lomb Corporation (Bausch Health Companies, Inc.), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Inc., and Otsuka Pharmaceutical Co., Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Evaporative Dry Eye Syndrome
- Aqueous Deficient Dry Eye Syndrome
By Drug
- Restasis
- Xiidra
- Cequa
- Eysuvis
- Tyrvaya & Others
By Dosage
- Eye drops
- Gels
- Capsules & Tablets
- Eye Solutions
- Ointments
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Sales Channel
- OTC
- Prescription
By Product
- Cyclosporine
- Topical Corticosteroids
- Artificial Tears
- Punctal Plugs
- Oral Omega Supplements
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- AbbVie, Inc.
- Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
- Novartis AG
- Sun Pharmaceuticals Industries Ltd.
- AFT Pharmaceuticals
- Santen Pharmaceutical Co., Ltd.
- Oyster Point Pharma, Inc.
- OASIS Medical, Inc.
- Otsuka Pharmaceutical Co., Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Dry Eye Syndrome Treatment Market by Type
Chapter 5. LAMEA Dry Eye Syndrome Treatment Market by Drug
Chapter 6. LAMEA Dry Eye Syndrome Treatment Market by Dosage
Chapter 7. LAMEA Dry Eye Syndrome Treatment Market by Distribution Channel
Chapter 8. LAMEA Dry Eye Syndrome Treatment Market by Sales Channel
Chapter 9. LAMEA Dry Eye Syndrome Treatment Market by Product
Chapter 10. LAMEA Dry Eye Syndrome Treatment Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- AbbVie, Inc.
- Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
- Novartis AG
- Sun Pharmaceuticals Industries Ltd.
- AFT Pharmaceuticals
- Santen Pharmaceutical Co., Ltd.
- Oyster Point Pharma, Inc.
- OASIS Medical, Inc.
- Otsuka Pharmaceutical Co., Ltd.
Methodology
LOADING...